New drug MK-6204 enters early human testing for hard-to-treat cancers

NCT ID NCT06726369

NEW Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen May 08, 2026 · Last updated May 08, 2026

Summary

This early-stage study tests a new drug called MK-6204 in about 90 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the drug alone, and researchers will monitor side effects and any signs of cancer control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, 100142, China

Contact

Contact
Chongqing University Cancer Hospital
NOT_YET_RECRUITING

Chongqing, China
Fujian Provincial Cancer Hospital
NOT_YET_RECRUITING

Fuzhou, China
Hubei Cancer Hospital
NOT_YET_RECRUITING

Wuhan, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, 410031, China
Shanghai East Hospital
NOT_YET_RECRUITING

Shanghai, China
West China Hospital of Sichuan University
NOT_YET_RECRUITING

Chengdu, China

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS